The overall performance of this batch of Chinese innovative drug stocks is relatively weak: BeiGene, Insilico Medicine, 3SBio, and Summit all saw slight declines, while WuXi AppTec edged up slightly. Hong Kong-listed biotech stocks have recently lacked new clinical or business development catalysts, and liquidity is also tight, leading the entire batch to follow sentiment in a slight pullback. The "selling picks and shovels" logic of CXO companies like WuXi AppTec is different from that of pure innovative drug companies, making them relatively more resilient to declines and barely able to turn positive.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
